Compare ARE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | KRYS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 7.8B |
| IPO Year | 1997 | 2017 |
| Metric | ARE | KRYS |
|---|---|---|
| Price | $52.42 | $256.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $58.78 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.8M | 270.3K |
| Earning Date | 04-27-2026 | 05-18-2026 |
| Dividend Yield | ★ 8.73% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | ★ $3,026,556,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $40.88 |
| Revenue Next Year | $0.52 | $35.16 |
| P/E Ratio | ★ N/A | $38.79 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $44.10 | $123.03 |
| 52 Week High | $105.14 | $298.30 |
| Indicator | ARE | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 44.20 |
| Support Level | $49.38 | $255.65 |
| Resistance Level | $54.86 | $293.60 |
| Average True Range (ATR) | 1.73 | 12.37 |
| MACD | -0.18 | -1.88 |
| Stochastic Oscillator | 50.43 | 16.38 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.